The BUD23 antibody targets the human BUD23 protein, also known as WBSCR20 or HUMORF20. encoded by the BUD23 gene located on chromosome 7q11.23 within the Williams-Beuren syndrome (WBS) critical region. BUD23 is a conserved S-adenosylmethionine-dependent methyltransferase involved in ribosomal RNA (rRNA) processing and ribosome biogenesis. It catalyzes the methylation of 18S rRNA at position G1575. a critical modification for proper 40S ribosomal subunit assembly and mRNA translation fidelity. Dysregulation of BUD23 has been linked to developmental disorders and cancers. For example, haploinsufficiency in WBS is associated with neurodevelopmental abnormalities, while BUD23 overexpression is observed in hepatocellular carcinoma and colorectal cancer, where it promotes tumor progression by enhancing ribosome production and cell proliferation. The BUD23 antibody is widely used in research to study ribosome biogenesis mechanisms, cancer biology, and cellular stress responses. It enables detection of BUD23 expression via techniques like Western blotting, immunofluorescence, and immunohistochemistry, aiding in the exploration of its role in diseases and potential therapeutic targeting.